TENAX THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On January 12, 2022, Tenax Therapeutics, Inc. (the "Company") issued a press release announcing that the United States Patent and Trademark Office has granted it a patent for the Company's subcutaneous formulation of levosimendan (TNX-102). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




Exhibit No.   Description
  99.1          Press Release dated January 12, 2022.

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses